Re-appointment of Mr. G V Prasad as Whole-Time Director designated as Co-Chairman & Managing Director
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited financial results for Q4 and FY25. FY25 consolidated revenues rose 17% YoY to Rs. 32,554 crore, driven by the newly acquired NRT (Nicotine Replacement Therapy) business from Haleon and steady growth in Global Generics. FY25 profit after tax attributable to shareholders was Rs. 5,654 crore, up 2% YoY. Q4 revenues grew 20% YoY to Rs. 8,506 crore with Q4 PAT up 22% YoY at Rs. 1,594 crore. A final dividend of Rs. 8 per share was recommended for FY25. Co-Chairman & MD G V Prasad, a promoter, was re-appointed for a fresh 5-year term effective January 30, 2026, subject to shareholder approval. The 41st AGM is scheduled for July 24, 2025, with July 10, 2025 as the record date for dividend eligibility. Makarand M Joshi & Co was appointed as Secretarial Auditors for a 5-year term starting April 1, 2025.
Strong FY25 performance with double-digit revenue growth and continued profitability, supported by the NRT acquisition. Stable promoter-led leadership and a modest dividend of Rs. 8/share are broadly positive signals for shareholders, though PAT growth was modest at 2% YoY.